Diabetes drug companies end partnership

Fri, 01 Feb 2008
One division of global drug company Merck has ended their partnership with Glenmark pharmaceuticals to develop type 2 diabetes drug Melogliptin. The future of the drug, which had reached phase II of clinical trials, is uncertain.

A press release from Glenmark Pharmaceutcials of Switzerland indicates that they and Merck Serono have terminated their on-going agreement to develop the drug. Merck have decided to re-focus their portfolio, and to steer away from further diabetes research and development.

The managing director and CEO of Glenmark, Glenn Saldanha, reportedly commented: "It is unfortunate to end our relationship with Merck Serono for GRC 8200 since they have contributed a lot of expertise in the development during the last year. The data package so far is very promising and we are confident of finding a co-development partner to take the molecule further during the course of the calendar year 2008."

It is expected that Glenmark will continue with trials .
Leave a Comment
Login via Facebook, Yahoo! and Hotmail
or
Have your full say in the Diabetes Forum
Your comments may be moderated. Please report any spam, illegal, offensive or libellous posts.